These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8518245)

  • 21. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium.
    Khoo SK; Coglan MJ; Wright GR; DeVoss KN; Battistutta D
    Med J Aust; 1998 Mar; 168(5):216-20. PubMed ID: 9539899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.
    Moorjani S; Dupont A; Labrie F; De Lignieres B; Cusan L; Dupont P; Mailloux J; Lupien PJ
    J Clin Endocrinol Metab; 1991 Aug; 73(2):373-9. PubMed ID: 1649840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
    Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
    J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of continuous oestradiol-medroxyprogesterone administration on plasma lipids and lipoproteins.
    Cano A; Fernandes H; Serrano S; Mahiques P
    Maturitas; 1991 Mar; 13(1):35-42. PubMed ID: 1861641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
    Haarbo J; Hassager C; Jensen SB; Riis BJ; Christiansen C
    Am J Med; 1991 May; 90(5):584-9. PubMed ID: 1827568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
    Hemelaar M; Kenemans P; de Bie L; van de Weijer PH; van der Mooren MJ
    Fertil Steril; 2006 Apr; 85(4):979-88. PubMed ID: 16580384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High density lipoprotein subfractions during oral and cutaneous administration of 17 beta-estradiol to menopausal women.
    Fåhraeus L; Wallentin L
    J Clin Endocrinol Metab; 1983 Apr; 56(4):797-801. PubMed ID: 6833462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
    Hirvonen E; Mälkönen M; Manninen V
    N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women.
    Jensen J; Riis BJ; Strøm V; Nilas L; Christiansen C
    Am J Obstet Gynecol; 1987 Jan; 156(1):66-71. PubMed ID: 3541623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
    Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
    Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic effects of continuous estradiol-progestin therapy in postmenopausal women.
    Sporrong T; Hellgren M; Samsioe G; Mattsson LA
    Obstet Gynecol; 1989 May; 73(5 Pt 1):754-8. PubMed ID: 2704503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern.
    Christiansen C; Riis BJ
    Br J Obstet Gynaecol; 1990 Dec; 97(12):1087-92. PubMed ID: 2126198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of transdermal oestradiol and oral progestogens on haemostasis variables.
    Kroon UB; Tengborn L; Rita H; Bäckström AC
    Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():32-7. PubMed ID: 9389781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum lipoprotein changes in climacteric women induced by sequential therapy with natural estrogens and medroxy-progesterone acetate or norgestrel.
    Vejtorp M; Christensen MS; Vejtorp L; Larsen JF
    Acta Obstet Gynecol Scand; 1986; 65(5):391-5. PubMed ID: 3535357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
    Brynhildsen J; Hammar M
    Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.